Table 6.
Neutralizing antibody titers: flavivirus-unprimed subjects (according to protocol cohort)
| PID | Group | DENV | Pre-vac | Post-dose 1 (month 1) | Post-dose 2 (month 7) |
|---|---|---|---|---|---|
| 90 | Placebo | DENV-1 | 5 | 5 | 5 |
| 90 | Placebo | DENV-2 | 5 | 5 | 5 |
| 90 | Placebo | DENV-3 | 5 | 5 | 5 |
| 90 | Placebo | DENV-4 | 5 | 5 | 5 |
| 111 | Placebo | DENV-1 | 5 | 5 | 5 |
| 111 | Placebo | DENV-2 | 5 | 5 | 5 |
| 111 | Placebo | DENV-3 | 5 | 5 | 5 |
| 111 | Placebo | DENV-4 | 5 | 5 | 5 |
| 112 | Placebo | DENV-1 | 5 | 5 | 5 |
| 112 | Placebo | DENV-2 | 5 | 5 | 5 |
| 112 | Placebo | DENV-3 | 5 | 5 | 5 |
| 112 | Placebo | DENV-4 | 5 | 5 | 5 |
| 36 | F17 | DENV-1 | 5 | 332 | 191 |
| 36 | F17 | DENV-2 | 5 | 1,552 | 376 |
| 36 | F17 | DENV-3 | 5 | 126 | 35 |
| 36 | F17 | DENV-4 | 5 | 2,430 | 2,430 |
| 37 | F17 | DENV-1 | 5 | 5 | 18 |
| 37 | F17 | DENV-2 | 5 | 2,430 | 441 |
| 37 | F17 | DENV-3 | 5 | 5 | 14 |
| 37 | F17 | DENV-4 | 5 | 2,430 | 516 |
| 42 | F17 | DENV-1 | 5 | 5 | 2,430 |
| 42 | F17 | DENV-2 | 5 | 5 | 47 |
| 42 | F17 | DENV-3 | 5 | 5 | 147 |
| 42 | F17 | DENV-4 | 5 | 5 | 139 |
| 46 | F17 | DENV-1 | 5 | 5 | 2,430 |
| 46 | F17 | DENV-2 | 5 | 5 | 1,439 |
| 46 | F17 | DENV-3 | 5 | 5 | 2,430 |
| 46 | F17 | DENV-4 | 5 | 624 | 2,430 |
| 113 | F17 | DENV-1 | 5 | 16 | 2,340 |
| 113 | F17 | DENV-2 | 5 | 5 | 2,430 |
| 113 | F17 | DENV-3 | 5 | 5 | 572 |
| 113 | F17 | DENV-4 | 5 | 2,430 | 1,706 |
| 97 | F19 | DENV-1 | 5 | 131 | 677 |
| 97 | F19 | DENV-2 | 5 | 23 | 2,430 |
| 97 | F19 | DENV-3 | 5 | 19 | 148 |
| 97 | F19 | DENV-4 | 5 | 2,430 | 2,430 |
Data collected at months 3 and 9 are not presented, because they were similar to data at months 1 and 7, respectively. PID = patient identification number; pre-vac = before dose 1.